SVRA Price / FCF | Savara Inc

Savara Inc Price-FCF Ratio

The price-to-free-cash-flow (P/FCF) ratio tells you how many dollars investors pay for each dollar of cash a company generates after paying for its capital spending. It is market capitalization divided by free cash flow over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher ratio means investors are paying more for each dollar of free cash flow; a negative ratio means the company spent more cash than it generated over those quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

Savara Inc price-fcf ratio for the quarter ending 2026-06-30 was -11.46, a change of -7.51 year-over-year.
Savara Inc price-fcf ratio for the quarter ending 2026-03-31 was -10.47, a change of -5.47 year-over-year.
Savara Inc price-fcf ratio for the quarter ending 2025-12-31 was -12.19, a change of -6.25 year-over-year.
Savara Inc price-fcf ratio for the quarter ending 2025-09-30 was -6.2, a change of 2.69 year-over-year.
Savara Inc price-fcf ratio for fiscal 2026 was -11.46.
Savara Inc price-fcf ratio for fiscal 2025 was -12.19, a change of -6.25 from fiscal 2024.
Savara Inc price-fcf ratio for fiscal 2024 was -5.94, a change of 6.7 from fiscal 2023.
Savara Inc price-fcf ratio for fiscal 2023 was -12.64.

Available history: 2017-06-30 to 2026-06-30
Data captured: 2026-06-30

Historical Price-FCF Ratio

Date	Price-FCF Ratio	Market capitalization	Free cash flow 12 month
2026-06-30	-11.46	$1.27B	-$110.66M
2026-03-31	-10.47	$1.12B	-$106.97M
2025-12-31	-12.19	$1.23B	-$101.06M
2025-09-30	-6.2	$615.3M	-$99.27M
2025-06-30	-3.95	$392.37M	-$99.41M
2025-03-31	-5	$478.39M	-$95.65M
2024-12-31	-5.94	$529.34M	-$89.11M
2024-09-30	-8.89	$724.37M	-$81.47M
2024-06-30	-7.74	$556.94M	-$72M
2024-03-31	-11.47	$688.12M	-$59.98M
2023-12-31	-12.64	$649.27M	-$51.36M
2023-09-30	-11.53	$511.58M	-$44.38M
2023-06-30	-9.27	$364.71M	-$39.34M
2020-12-31	-1.56	$62.28M	-$39.88M
2020-09-30	-1.57	$59.01M	-$37.53M
2020-06-30	-3.11	$131.53M	-$42.23M
2020-03-31	-2.27	$107.79M	-$47.4M
2019-12-31	-5.03	$227.54M	-$45.27M
2019-09-30	-2.38	$109.2M	-$45.87M
2019-06-30	-2.13	$92.2M	-$43.23M
2019-03-31	-6.49	$264.07M	-$40.68M
2018-12-31	-6.75	$266.06M	-$39.42M
2018-09-30	-10.11	$391.95M	-$38.77M
2018-06-30	-9.13	$349.07M	-$38.24M
2018-03-31	-7.93	$281.56M	-$35.52M
2017-12-31	-15.76	$452.76M	-$28.73M
2017-09-30	-10.85	$228.04M	-$21.02M
2017-06-30	-9.1	$142.32M	-$15.63M

Annual Price-FCF Ratio

Date	Price-FCF Ratio	Market capitalization	Free cash flow 12 month
2026-06-30	-11.46	$1.27B	-$110.66M
2025-12-31	-12.19	$1.23B	-$101.06M
2024-12-31	-5.94	$529.34M	-$89.11M
2023-12-31	-12.64	$649.27M	-$51.36M
2020-12-31	-1.56	$62.28M	-$39.88M
2019-12-31	-5.03	$227.54M	-$45.27M
2018-12-31	-6.75	$266.06M	-$39.42M
2017-12-31	-15.76	$452.76M	-$28.73M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
MoonLake Immunotherapeutics (MLTX)	Switzerland	$1.031B	-5.43
MANNKIND CORP (MNKD)	United States	$1.058B	-30.41
Alto Neuroscience, Inc. (ANRO)	United States	$1.065B	-11.02
Pacira BioSciences, Inc. (PCRX)	United States	$1.020B	69.03
Janux Therapeutics, Inc. (JANX)	United States	$1.019B	-9.15
Corvus Pharmaceuticals, Inc. (CRVS)	United States	$0.994B	-23.25
Amphastar Pharmaceuticals, Inc. (AMPH)	United States	$1.116B	10.93
Kura Oncology, Inc. (KURA)	United States	$0.967B	-3.29
Arbutus Biopharma Corp (ABUS)		$0.965B	6.19
Seaport Therapeutics, Inc. (SPTX)	United States	$1.131B